Treating Multiple Myeloma in North Africa, the Middle East, and Europe

Emerging and Practical Concepts in Multiple Myeloma


In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.

Date and Location

9–10 April 2021, Virtual Meeting

Meeting Content

View the slides and watch the video of Day 1

View the slides and watch the video of Day 2


Rafael Fonseca

Rafael Fonseca, MD

Mayo Clinic Cancer Center, USA

Majed Alahmadi

Majed Alahmadi, MD

King Abdulaziz Medical City,
Kingdom of Saudi Arabia

Irene Ghobrial

Irene Ghobrial, MD

Dana-Farber Cancer Institute, USA

Mervat Mattar

Mervat Mattar, MD

Cairo University, Egypt

María-Victoria Mateos, MD, PhD

María-Victoria Mateos, MD, PhD

University of Salamanca, Spain

Mohamad Mohty MD

Mohamad Mohty MD

Saint-Antoine Hospital and Sorbonne University, Paris, France

Keith Stewart

Keith Stewart, MD

Princess Margaret Cancer Centre, Canada


This virtual program will take place over 2 days.

Day 1: Minimal Residual Disease, Frontline Therapies, and the Role of Transplantation

Day 2: Management of High-Risk, Relapsed, and Heavily Pretreated Multiple Myeloma, New and Future Therapies, and Patient Case Discussion

Day 1: Friday, April 9, 2021

16.00 – 18.30 CET / 17.00 – 19.30 AST (UTC+3)

KSA time (UTC+3) Topic Presenter
17.00 – 17.15 Welcome and Meeting Overview Rafael Fonseca
17.15 – 17.35 Smoldering Multiple Myeloma
• Diagnosis, criteria, and when and how to intervene
Irene Ghobrial
17.35 – 17.55 Role of Minimal Residual Disease in Multiple Myeloma
• Prognostic value, clinical relevance, and MRD-driven therapeutic guidance
Majed Alahmadi
17.55 – 18.15 Frontline Therapy for Newly Diagnosed Transplant-Eligible Multiple Myeloma: The Role of Transplantation
• Guidelines, induction therapies, and how and when to transplant
Mervat Mattar
18.15 – 18.35 Optimal Use of Consolidation and Maintenance Therapy
• Evolving insights in consolidation and maintenance treatment after transplant
Mohamad Mohty
18.35 – 18.50 Break  
18.50 – 19.15 Frontline Therapy for Newly Diagnosed Transplant-Ineligible Patients
• Criteria, guidelines, and treatment choices
Keith Stewart
19.15 – 19.30 Session Close Rafael Fonseca

Day 2: Saturday, April 10, 2021

16.00 – 19.15 CET / 17.00 – 20.15 AST (UTC+3)

KSA time (UTC+3) Topic Presenter
17.00 – 17.10 Session Open Rafael Fonseca
17.10 – 17.30 Identification and Special Considerations for High-Risk Multiple Myeloma
• Risk stratification, prognosis, and treatment choices
María-Victoria Mateos
17.30 – 17.55 Management of Early Relapse of Multiple Myeloma
• Definition, prognosis, and treatment choices
Rafael Fonseca
17.55 – 18.20 Management of Heavily Pretreated Multiple Myeloma
• Optimal use of treatment choices in relapsed/refractory multiple myeloma, excluding T-cell engagers
Keith Stewart
18.20 – 18.30 Break  
18.30 – 19.20 New and Future Therapies for Multiple Myeloma
• Latest trial updates, and upcoming and promising new strategies, including T-cell engagers
Irene Ghobrial
19.20 – 20.00 Patient Case Discussion: Relapsed/Refractory Multiple Myeloma
• Treatment challenges in relapsed/refractory MM in the region (10 min)
• Cases from the region will be discussed with the faculty – “tumor board approach” (30 min)
All faculty
20.00 – 20.15 Session Close Rafael Fonseca